Xinbo Yang

Xinbo Yang is an Assistant Professor in the Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center (MSKCC) and Weill Cornell Medicine's Graduate School of Medical Sciences. His research focuses on understanding T cell receptor (TCR) specificity in cancer and autoimmune disease, using interdisciplinary approaches including antigen-discovery platforms, protein engineering techniques, and structural biology tools.

Dr. Yang received his PhD from the University of Maryland College Park. His educational background has prepared him for cutting-edge research at the intersection of immunology, structural biology, and cancer therapeutics.

Dr. Yang's research program centers on how T cells distinguish between self and foreign antigens. The lab investigates the molecular basis of T cell receptor recognition in both cancer and autoimmune contexts. By studying how T cells scan host tissues to eliminate infected or malignant cells, the Yang lab aims to understand the mechanisms behind immune evasion in cancer and inappropriate immune responses in autoimmunity. The lab develops antigen-discovery platforms to identify targets for 'orphan' TCRs, which allows for specific perturbation of targets to study T cell responses. This work has significant implications for understanding disease pathogenesis and developing pMHC-based therapeutics.

Analysis of Dr. Yang's recent publications reveals a strong focus on T cell receptor biology, structural immunology, and cancer immunotherapy. His work spans multiple disease contexts including cancer, autoimmune disorders, and infectious diseases. A recurring theme is the application of structural biology and protein engineering to understand and manipulate T cell recognition. His research bridges basic science with translational applications, particularly in developing novel immunotherapies.

• PhD, University of Maryland College Park

Dr. Yang leads the Xinbo Yang Lab, which is part of the Molecular Pharmacology Program at MSKCC. The lab includes research staff such as Emily Howie, a Research Technician. The lab collaborates extensively with other researchers at MSKCC and beyond, as evidenced by the co-authorship patterns in publications. Dr. Yang has disclosed financial interests with 3T Biosciences where he holds equity, suggesting potential commercial applications of his research.